TGen-UCSF study uses genomics to make treatment calls for recurrent glioblastoma patients

(The Translational Genomics Research Institute) Several patients with recurring glioblastoma, a deadly brain cancer, survived for more than a year in a clinical trial believed to be the first to use comprehensive DNA and RNA sequencing of a patient's tumor to inform treatment for these patients in real-time. The study was led by the Translational Genomics Research Institute (TGen), UC San Francisco (UCSF) and the Ivy Foundation Early Phase Clinical Trials Consortium.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news